DK2999699T3 - Purindioner som wnt-vej-modulatorer - Google Patents
Purindioner som wnt-vej-modulatorer Download PDFInfo
- Publication number
- DK2999699T3 DK2999699T3 DK14801575.3T DK14801575T DK2999699T3 DK 2999699 T3 DK2999699 T3 DK 2999699T3 DK 14801575 T DK14801575 T DK 14801575T DK 2999699 T3 DK2999699 T3 DK 2999699T3
- Authority
- DK
- Denmark
- Prior art keywords
- purindions
- wnt
- modulators
- road
- wnt road
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1309333.1A GB201309333D0 (en) | 2013-05-23 | 2013-05-23 | Purine diones as WNT pathway modulators |
| PCT/SG2014/000217 WO2014189466A1 (en) | 2013-05-23 | 2014-05-19 | Purine diones as wnt pathway modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2999699T3 true DK2999699T3 (da) | 2020-07-13 |
Family
ID=48784655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14801575.3T DK2999699T3 (da) | 2013-05-23 | 2014-05-19 | Purindioner som wnt-vej-modulatorer |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9926320B2 (da) |
| EP (1) | EP2999699B1 (da) |
| JP (1) | JP6506742B2 (da) |
| KR (2) | KR102062262B1 (da) |
| CN (2) | CN105452248A (da) |
| AU (2) | AU2014269134B2 (da) |
| BR (1) | BR112015029182B1 (da) |
| CA (1) | CA2912757C (da) |
| DK (1) | DK2999699T3 (da) |
| ES (1) | ES2802923T3 (da) |
| GB (1) | GB201309333D0 (da) |
| SG (1) | SG11201509593TA (da) |
| WO (1) | WO2014189466A1 (da) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
| GB201322334D0 (en) * | 2013-12-17 | 2014-01-29 | Agency Science Tech & Res | Maleimide derivatives as modulators of WNT pathway |
| TWI676626B (zh) * | 2014-04-23 | 2019-11-11 | 美商美國禮來大藥廠 | 抑制瞬時受體電位ａ１離子通道 |
| US10221177B2 (en) * | 2014-09-19 | 2019-03-05 | Hydra Biosciences, Inc. | Inhibiting the transient receptor potential A1 ion channel |
| CN105440034B (zh) * | 2015-11-16 | 2017-08-15 | 山东罗欣药业集团股份有限公司 | 一种利格列汀及其中间体的制备方法 |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| CN106632332B (zh) * | 2016-09-26 | 2018-07-06 | 杭州新博思生物医药有限公司 | 一种伊曲茶碱的制备方法 |
| CN111247148B (zh) * | 2017-09-14 | 2022-12-20 | 新加坡科技研究局 | Wnt通路调节剂 |
| EP3746445A1 (en) | 2018-01-31 | 2020-12-09 | Eli Lilly And Company | Inhibiting the transient receptor potential a1 ion channel |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| CN114072131B (zh) * | 2019-05-22 | 2024-03-19 | 新加坡科技研究局 | 口服制剂、其制备方法及其用途 |
| WO2020236078A1 (en) * | 2019-05-22 | 2020-11-26 | Agency For Science, Technology And Research | Pharmaceutical combination |
| WO2021004467A1 (zh) * | 2019-07-08 | 2021-01-14 | 南京明德新药研发有限公司 | 作为porcupine抑制剂的化合物及其应用 |
| EP4069243A4 (en) * | 2020-01-08 | 2023-12-27 | Agency for Science, Technology and Research | COMBINATION THERAPY |
| WO2023072263A1 (zh) * | 2021-10-29 | 2023-05-04 | 南京明德新药研发有限公司 | 5-取代的吡啶-2(1h)-酮类化合物及其应用 |
| CN114671875A (zh) * | 2022-04-27 | 2022-06-28 | 成都施贝康生物医药科技有限公司 | 新型二氢嘧啶类化合物、异构体或盐及其制备方法和用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| WO2007073505A2 (en) | 2005-12-22 | 2007-06-28 | Hydra Biosciences, Inc. | Trpa1 inhibitors for treating pain |
| DK2170309T3 (da) * | 2007-06-22 | 2017-01-09 | Hydra Biosciences Inc | 2,6-dioxo,-2,3-dihydro-1h-purinforbindelser anvendelige til behandling af sygdomme relateret til aktiviteten af trpa1-kanalen |
| CN101909630A (zh) * | 2007-11-02 | 2010-12-08 | 新加坡科技研究局 | 预防和治疗肿瘤的方法和化合物 |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US20120108614A1 (en) | 2008-05-14 | 2012-05-03 | Chong Jayhong A | Compounds and compositions for treating chemical warfare agent-induced injuries |
| US20120046305A1 (en) | 2008-09-24 | 2012-02-23 | Moran Magdalene M | Methods and compositions for treating respiratory disorders |
| US8362025B2 (en) | 2008-12-22 | 2013-01-29 | Hydra Biosciences, Inc. | Compositions useful for treating disorders related to TRPA1 |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| UY33469A (es) | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| CN103261201B (zh) * | 2010-12-20 | 2015-04-22 | 格兰马克药品股份有限公司 | 作为trpa1拮抗剂的2-氨基-4-芳基噻唑化合物 |
| WO2012172475A1 (en) * | 2011-06-13 | 2012-12-20 | Glenmark Pharmaceuticals S.A. | Treatment of respiratory disorders using trpa1 antagonists |
| US20140148423A1 (en) * | 2011-07-25 | 2014-05-29 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition comprising a trpa1 antagonist and a steroid |
| AR087501A1 (es) * | 2011-08-09 | 2014-03-26 | Hydra Biosciences Inc | Compuestos inhibidores del canal ionico del potencial receptor transitorio trpa1 |
| PT2755483T (pt) | 2011-09-14 | 2019-02-18 | Samumed Llc | Indazol-3-carboxamidas e sua utilização como inibidores da via de sinalização de wnt/β-catenina |
| US9265772B2 (en) | 2012-05-11 | 2016-02-23 | Reset Therapeutics, Inc. | Carbazole-containing sulfonamides as cryptochrome modulators |
| GB201309333D0 (en) | 2013-05-23 | 2013-07-10 | Agency Science Tech & Res | Purine diones as WNT pathway modulators |
-
2013
- 2013-05-23 GB GBGB1309333.1A patent/GB201309333D0/en not_active Ceased
-
2014
- 2014-05-19 KR KR1020157035961A patent/KR102062262B1/ko active Application Filing
- 2014-05-19 KR KR1020197038593A patent/KR102153989B1/ko active IP Right Grant
- 2014-05-19 SG SG11201509593TA patent/SG11201509593TA/en unknown
- 2014-05-19 JP JP2016515318A patent/JP6506742B2/ja active Active
- 2014-05-19 BR BR112015029182-1A patent/BR112015029182B1/pt active IP Right Grant
- 2014-05-19 ES ES14801575T patent/ES2802923T3/es active Active
- 2014-05-19 CN CN201480041283.2A patent/CN105452248A/zh active Pending
- 2014-05-19 CA CA2912757A patent/CA2912757C/en active Active
- 2014-05-19 CN CN201910142080.7A patent/CN109776537B/zh active Active
- 2014-05-19 EP EP14801575.3A patent/EP2999699B1/en active Active
- 2014-05-19 US US14/893,172 patent/US9926320B2/en active Active
- 2014-05-19 DK DK14801575.3T patent/DK2999699T3/da active
- 2014-05-19 AU AU2014269134A patent/AU2014269134B2/en active Active
- 2014-05-19 WO PCT/SG2014/000217 patent/WO2014189466A1/en active Application Filing
-
2017
- 2017-08-03 US US15/668,260 patent/US10472360B2/en active Active
- 2017-08-28 AU AU2017219132A patent/AU2017219132B2/en active Active
-
2018
- 2018-02-20 US US15/899,675 patent/US10526335B2/en active Active
-
2019
- 2019-12-16 US US16/716,268 patent/US10844063B2/en active Active
-
2020
- 2020-11-20 US US17/100,474 patent/US11555037B2/en active Active
-
2022
- 2022-12-08 US US18/077,921 patent/US20230174533A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2999699T3 (da) | Purindioner som wnt-vej-modulatorer | |
| CL2014001353S1 (es) | Neumatico | |
| DK3848027T3 (da) | Octahydro-kondenserede azadecalinglucocorticoidreceptormodulatorer | |
| DE102013020972A8 (de) | Chirpmodulation | |
| CL2014001622S1 (es) | Neumatico | |
| CL2014000677S1 (es) | Neumatico | |
| ES2694001T9 (es) | Moduladores de LXR | |
| DK3007725T3 (da) | Beta-glycolipider til anvendelse som adjuvanser | |
| DK3083808T3 (da) | Tætningsmiddelsammensætning | |
| UA28664S (uk) | Ліхтар автотранспортного засобу | |
| UA28663S (uk) | Ліхтар автотранспортного засобу | |
| UA28662S (uk) | Ліхтар автотранспортного засобу | |
| UA28661S (uk) | Ліхтар автотранспортного засобу | |
| UA28660S (uk) | Ліхтар автотранспортного засобу | |
| UA28659S (uk) | Ліхтар автотранспортного засобу | |
| UA28289S (uk) | Ліхтар автотранспортного засобу | |
| UA28291S (uk) | Ліхтар автотранспортного засобу | |
| UA28281S (uk) | Ліхтар автотранспортного засобу | |
| UA28282S (uk) | Ліхтар автотранспортного засобу | |
| UA28285S (uk) | Ліхтар автотранспортного засобу | |
| UA28280S (uk) | Ліхтар автотранспортного засобу | |
| UA26238S (uk) | Ліхтар автотранспортного засобу | |
| UA27593S (uk) | Ліхтар автотранспортного засобу | |
| UA27592S (uk) | Ліхтар автотранспортного засобу | |
| UA27506S (uk) | Ліхтар автотранспортного засобу |